Renal Cell Carcinoma

Oncology·MeSH: Carcinoma, Renal Cell

Prevalence

48.0 / 100K

Incidence

15.0 / 100K/yr

64 drugs in development·37 companies·44 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
afinitor	Novartis AG (NVS)
axitinib	Aptinyx Inc. (APTX)
Aybintio (SB8)	Organon & Co. (OGN)
CABOMETYX	EXELIXIS, INC. (EXEL)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
proleukin	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
sodium	Amneal Pharmaceuticals, Inc. (AMRX)
sodium nitroprusside	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(21)

Drug	Company
avelumab	CG Oncology, Inc. (CGON)
Balstilimab	ENANTA PHARMACEUTICALS INC (ENTA)
cabozantinib	GH Research PLC (GHRS)
Cabozantinib	BRISTOL MYERS SQUIBB CO (BMY)
Cabozantinib S-malate	Royalty Pharma plc (RPRX)
Casdatifan	ASTRAZENECA PLC (AZN)
casdatifan (AB521)	Arcus Biosciences, Inc. (RCUS)
Cetuximab Sarotalocan Sodium	Amneal Pharmaceuticals, Inc. (AMRX)
clostridium butyricum cbm 588 probiotic strain	GH Research PLC (GHRS)
epacadostat	Incyte Corp. (INCY)
Erlotinib	Amneal Pharmaceuticals, Inc. (AMRX)
Evolocumab	UNITED THERAPEUTICS Corp (UTHR)
lenvatinib	GH Research PLC (GHRS)
pazopanib	Incyte Corp. (INCY)
Pumitamig	BRISTOL MYERS SQUIBB CO (BMY)
rocapuldencel-t	ARGOS THERAPEUTICS INC (ARGS)
savolitinib	ASTRAZENECA PLC (AZN)
Sturlimogene Erparepvec	Replimune Group, Inc. (REPL)
tivozanib	AVEO PHARMACEUTICALS, INC. (AVEO)
Tivozanib	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Zanzalintinib	Merck & Co., Inc. (MRK)

Phase 2(13)

Drug	Company
ABT-869	AbbVie Inc. (ABBV)
ALLO-316	Allogene Therapeutics, Inc. (ALLO)
ALLO-647	Allogene Therapeutics, Inc. (ALLO)
balstililmab	AGENUS INC (AGEN)
Botensilimab	ENANTA PHARMACEUTICALS INC (ENTA)
cabozantinib	CG Oncology, Inc. (CGON)
Cyclophophamide	Allogene Therapeutics, Inc. (ALLO)
Erlotinib	ADMA BIOLOGICS, INC. (ADMA)
Fludarabine	Allogene Therapeutics, Inc. (ALLO)
lenvatinib	CG Oncology, Inc. (CGON)
Sodium Fluoride F-18	Amneal Pharmaceuticals, Inc. (AMRX)
Sodium Fluoride F-18	ADMA BIOLOGICS, INC. (ADMA)
Tivozanib	Replimune Group, Inc. (REPL)

Phase 1(14)

Drug	Company
AB521	EXELIXIS, INC. (EXEL)
ADI-270	Adicet Bio, Inc. (ACET)
ARO-HIF2	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
arx305	Ambrx Biopharma Cayman, Inc. (AMAM)
Balstilimab	AGENUS INC (AGEN)
Botensilimab	AGENUS INC (AGEN)
Cabozantinib	Arcus Biosciences, Inc. (RCUS)
Casdatifan	Arcus Biosciences, Inc. (RCUS)
CTX131	CRISPR Therapeutics AG (CRSP)
dcc-2812	Deciphera Pharmaceuticals, Inc. (DCPH)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)
ko-2806	Kura Oncology, Inc. (KURA)
XmAb819	Xencor Inc (XNCR)
zanzalintinib	EXELIXIS, INC. (EXEL)

Preclinical(4)

Drug	Company
anti-caix	Checkpoint Therapeutics, Inc. (CKPT)
anti-caix antibody	Checkpoint Therapeutics, Inc. (CKPT)
io112	IO Biotech, Inc. (IOBT)
oncr-021	Oncorus, Inc. (ONCR)

Unknown(1)

Drug	Company
cabozantinib	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 1/Phase 2(2)

Drug	Company
gen1160	GENMAB A/S (GNMSF)
gen1160	Genmab A/S (GMAB)

Phase 4(1)

Drug	Company
bms-986506	BRISTOL MYERS SQUIBB CO (BMY)

BioSniper tracks 64 drugs in development for Renal Cell Carcinoma across 37 companies.

There are 44 clinical trials targeting Renal Cell Carcinoma tracked by BioSniper.

The estimated prevalence of Renal Cell Carcinoma is approximately 48.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.